Pharmaceutical Technology
OCTOBER 6, 2022
from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.
Drug Discovery World
JULY 29, 2022
A team led by researchers at HMS and the Broad has just accomplished the rare feat of connecting those dots for one important gut bacterium. The usual suspects for triggering an immune response would be a protein or a sugar,” said Clardy. The work introduces new possibilities for developing drugs that piggyback on A.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 4, 2020
Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.
XTalks
NOVEMBER 6, 2020
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The bacterium then secretes pDNA-protein complexes, triggering an immune response to treat and prevent infection associated with the delivered genes.
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.
pharmaphorum
OCTOBER 5, 2022
million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium.
XTalks
NOVEMBER 10, 2020
Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. Adjuvants are used to help stimulate stronger vaccine immune responses. Typically, vaccine development involves the use of chicken eggs to propagate a virus.
Expert insights. Personalized for you.
147 
Let's personalize your content